Study of Acarbose in Longevity
关键词
抽象
描述
Acarbose, an FDA approved drug for the treatment of type 2 diabetes, has known effects on glucose metabolism. Evidence from mice indicates that acarbose may prolong lifespan. In humans, acarbose improves inflammatory markers and reduces cardiovascular events. Consequently, acarbose is of interest in clinical translational aging research since it may influence fundamental processes that contribute to age-related diseases. The study described herein is an exploratory study to examine the effect of acarbose treatment on the biology of aging in humans. Specifically, the investigators plan to study whether treatment with a 10 week course of acarbose will alter the gene expression profile in adipose tissue and muscle in older adults in pathways that are known to be affected by human aging, in a placebo-controlled crossover study.
日期
| 最后验证: | 06/30/2020 |
| 首次提交: | 09/08/2016 |
| 提交的预估入学人数: | 10/30/2016 |
| 首次发布: | 11/01/2016 |
| 上次提交的更新: | 07/12/2020 |
| 最近更新发布: | 07/14/2020 |
| 实际学习开始日期: | 11/21/2016 |
| 预计主要完成日期: | 12/25/2019 |
| 预计完成日期: | 12/25/2019 |
状况或疾病
干预/治疗
Drug: Acarbose
Other: Placebo
相
手臂组
| 臂 | 干预/治疗 |
|---|---|
| Other: Acarbose first Participants will take acarbose three times daily for 10 weeks (titration over 4 weeks, maintenance 6 weeks). After a two week washout, participants will take placebo three times daily for a total of 10 weeks (titration over 4 weeks, maintenance 6 weeks). | |
| Other: Placebo first Participants will take placebo three times daily for 10 weeks (titration over 4 weeks, maintenance 6 weeks). After a two week washout, participants will take acarbose three times daily for a total of 10 weeks (titration over 4 weeks, maintenance 6 weeks). |
资格标准
| 有资格学习的年龄 | 60 Years 至 60 Years |
| 有资格学习的性别 | Male |
| 接受健康志愿者 | 是 |
| 标准 | Inclusion Criteria: - Male - age >60 years - impaired fasting glucose (IFG) or impaired glucose tolerance (IGT) Exclusion Criteria: - cancer - heart failure - COPD - inflammatory conditions - eGFR<45 - active liver disease - poorly controlled hypertension - epilepsy - recent cardiovascular disease event (last 6 months) - inflammatory bowel disease - history of bariatric or other gastric surgery - cigarette smoking - serious substance abuse. - Treatment with drugs known to influence glucose metabolism - Hypersensitivity to acarbose or any component of the formulation. - Treatment with anti-coagulant medications or anti-platelet drugs |
结果
主要结果指标
1. Tissue gene expression after placebo vs after acarbose. [10 weeks]
次要成果指标
1. Serum microRNA [10 weeks]
2. Fecal microbiome [10 weeks]
